Literature DB >> 1493919

Comparative responses of human and rabbit interleukin-1 in vivo: effect of a recombinant interleukin-1 receptor antagonist.

C von Uexküll1, S Nourshargh, T J Williams.   

Abstract

The ability of recombinant human and rabbit interleukin-1 alpha (IL-1 alpha) in inducing inflammatory responses in rabbit skin were compared. Intradermal (i.d.) injections of recombinant human IL-1 alpha and recombinant rabbit IL-1 alpha induced intense accumulation of 111In-labelled neutrophils which was dependent on the dose of the cytokines administered. Both forms of IL-1 alpha induced very small levels of plasma protein leakage. Co-injection of the cytokines with the mRNA synthesis inhibitor actinomycin D (Act D) attenuated the number of neutrophils accumulating in response to both human and rabbit forms of IL-1 alpha. Local injection of a recombinant human IL-1 receptor antagonist (IL-1Ra) caused a dose-dependent inhibition of local inflammatory responses initiated by human and rabbit IL-1 alpha s well as rabbit IL-1 beta indicating the species cross-reactivity of the antagonist. IL-1Ra was selective for IL-1 in rabbit skin, as responses induced by C5ades Arg and formyl-methionyl-leucyl-phenylalanine (FMLP) were not inhibited. IL-1Ra significantly inhibited the IL-1-induced neutrophil accumulation only when co-injected with the cytokine. The local administration of the antagonist 30 min after rabbit IL-1 alpha failed to inhibit the inflammatory response. These results suggest that the in vivo events leading to the accumulation of neutrophils in response to IL-1 alpha are rapidly initiated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493919      PMCID: PMC1421664     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

Review 1.  The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome.

Authors:  C A Dinarello
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

3.  Inflammatory edema induced by interactions between IL-1 and the neuropeptide calcitonin gene-related peptide.

Authors:  T L Buckley; S D Brain; P D Collins; T J Williams
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

4.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist.

Authors:  S P Eisenberg; R J Evans; W P Arend; E Verderber; M T Brewer; C H Hannum; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

Review 5.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

6.  Characterization of a human interleukin 1 inhibitor.

Authors:  Z Liao; A Haimovitz; Y Chen; J Chan; D L Rosenstreich
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

7.  The sequential generation of neutrophil chemoattractant proteins in acute inflammation in the rabbit in vivo. Relationship between C5a and proteins with the characteristics of IL-8/neutrophil-activating protein 1.

Authors:  P D Collins; P J Jose; T J Williams
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

8.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.

Authors:  G Wakabayashi; J A Gelfand; J F Burke; R C Thompson; C A Dinarello
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

Review 9.  Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.

Authors:  W P Arend
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.

Authors:  K Matsushima; K Morishita; T Yoshimura; S Lavu; Y Kobayashi; W Lew; E Appella; H F Kung; E J Leonard; J J Oppenheim
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  5 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

Review 2.  Role of the nitric oxide/cyclic GMP/Ca2+ signaling pathway in the pyrogenic effect of interleukin-1beta.

Authors:  Mitri Palmi; Antonella Meini
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

3.  Effect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions.

Authors:  K E Norman; T J Williams; M Feldmann; A G Rossi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

4.  Interleukin-1 beta stimulation of 45Ca2+ release from rat striatal slices.

Authors:  M Plami; M Frosini; G Sgaragli
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  LPS-induced 111In-eosinophil accumulation in guinea-pig skin: evidence for a role for TNF-alpha.

Authors:  V B Weg; D T Walsh; L H Faccioli; T J Williams; M Feldmann; S Nourshargh
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.